Trending News
News

News
In Vitro Diagnostics Industry Welcomes Pathology Report
The British In Vitro Diagnostics Association has welcomes the publication of the report of the second phase of Lord Carter’s Independent Review of Pathology Services.

News
Champions Biotechnology Partners to Establish Agreements for Preclinical Evaluation of Oncology Drugs
Champions Biotechnology’s Biomerk Tumorgrafts™ will be utilized by the Centocor for the preclinical evaluation of certain therapeutic agents.

News
Abbott Exercises its Option to Acquire IBIS Biosciences, a Subsidiary of ISIS
The acquisition worth $215 million will expand Abbott's position in molecular diagnostics for infectious disease.

News
Confusing Risk Information may Lead to Poor Cancer Treatment Choices
Tools designed to help guide treatment decisions are too complex for most patients to understand, U-M study finds.

News
Study Sheds Light on Causes of HIV Dementia
Einstein researchers clarify how two major variants of HIV differ in their ability to cause neurologic complications.

News
DxS and Amgen Enter into Collaboration to Provide a K-RAS Companion Diagnostic for Vectibix® in the United States
Companies plan to work together to further facilitate the use of Vectibix® in metastatic colorectal cancer patients with wild-type K-RAS status.

News
Compugen and Merck Serono to Collaborate on Novel Peptide for the Treatment of Inflammatory Diseases
The agreement provides Merck Serono with an option to exclusively license CGEN 855 peptide for worldwide development and commercialization.

News
Overweight Women at Increased Risk of Advanced Breast Cancer
A study of over 280,000 women showed that postmenopausal obese women have advanced breast cancer at significantly higher rates than women of normal weight.

News
Roche Signs Definitive Agreement to Acquire Memory Pharmaceuticals
Roche to acquire all the outstanding shares of Memory Pharmaceuticals for approximately USD 50 million.

News
Lilly Completes Acquisition of ImClone Systems
The acquisition will broaden Lilly's portfolio of marketed cancer therapies and oncology pipeline with up to three targeted therapies in Phase III in 2009.
Advertisement